Please assess the completion status of the following clinical trial:

Trial Title: Apremilast in the Treatment of Uveitis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with vision-threatening autoimmune uveitis~* failure to respond to prednisone and at least one other systemic immunosuppressive, or intolerance to such medications due to side effects~Exclusion Criteria:~* serious concomitant illness that could interfere with the subject's participation~* previous or current use of an alkylating agent~* use of CYP3A4 inhibitors during the trial~* TNF blocker use within the 8 weeks prior to enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Patients receiving apremilast.

Based on this trial design, predict the completion outcome and termination type (if applicable).